I recently found 3 studies to the use of nolvadex for pubertal gyno on teenage boys...the studies had more than a 90% success rate with no side effects noted. Check this out...Im 18...have mild pubertal gyno and now REALLY considering getting nolvadex to cure this.
Horm Res. 2002;57(5-6):187-91. Related Articles, Links
Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia.
Novoa FJ, Boronat M, Carrillo A, Tapia M, Diaz-Cremades J, Chirino R.
Department of Endocrinology, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain. email@example.com
BACKGROUND/AIM: The estrogenic actions of tamoxifen on lipid profiles and hemostasis have been extensively demonstrated in women. Due to limited experience with this drug in males, it is uncertain whether these effects are also present in men. The aim of our study was to assess the response of blood lipids, lipoproteins, and coagulation parameters in a group of men taking tamoxifen. METHODS: We studied 15 healthy boys with pubertal gynecomastia who were given 10 mg tamoxifen per day. Total testosterone, sex-hormone-binding globulin, estradiol, serum lipids, apolipoprotein B, apolipoprotein A-I, lipoprotein(a), fibrinogen, antithrombin III, von Willebrand factor, and markers of activated coagulation and fibrinolysis were determined at baseline and 1 and 3 months after beginning of the tamoxifen treatment. RESULTS: Total cholesterol and lipoprotein(a) showed moderate but significant decreases from baseline. Low-density lipoprotein and high-density lipoprotein cholesterol concentrations as well as triglyceride and apolipoprotein B levels became lower, but these changes were not statistically significant. Among clotting parameters, antithrombin III was reduced, and von Willebrand factor increased significantly. Markers of activated coagulation and fibrinolysis remained unchanged throughout the period of therapy. CONCLUSIONS: The effects of tamoxifen on blood lipids and hemostasis we found in this group of healthy young men were qualitatively similar, but lesser than those previously described in women. Copyright 2002 S. Karger AG, Basel
Then show him this so he'll give you the nolvadex:
Klin Padiatr. 1987 Nov-Dec;199(6):389-91. Related Articles, Links
[Treatment of marked gynecomastia in puberty with tamoxifen]
[Article in German]
Konig R, Schonberger W, Neumann P, Benes P, Grimm W.
Kinderklinik, Universitat Mainz.
Based on the good results of another author 10 boys with marked pubertal gynecomastia were treated with the antioestrogen Tamoxifen (Nolvadex) at a dose of 20-40 mg/d orally for 2-12 months. In most cases the gynecomastia decreased totally, only two patients experienced palpable subareolar glandular tissue at the end of therapy. Side effects were not noted. During therapy levels of estradiol and testosteron increased, with a more pronounced elevation of estradiol. Basal values of LH and FSH remained nearly unchanged, but LH showed an increased response to LH-RH, which could be explained by the antioestrogenic effect of Tamoxifen at the hypothalamic level. The reduction of breast size in spite of increased estradiol levels on the other hand, suggests that the mean therapeutic effect of tamoxifen is through estrogen receptor blockade of breast tissue.
Dtsch Med Wochenschr. 1984 Nov 2;109(44):1678-82. Related Articles, Links
[Testosterone and estradiol levels in male gynecomastia. Clinical and endocrine findings during treatment with tamoxifen]
[Article in German]
Eversmann T, Moito J, von Werder K.
Oestradiol-(E2) levels in serum were significantly higher in a group of 91 males with gynaecomastia than in a control group. The levels were highest in patients with testicular tumour, hyperprolactinaemia and idiopathic gynaecomastia. In gynaecomastia of puberty and primary or secondary hypogonadism, the E2 level was within normal limits, but the testosterone/oestradiol ratio was significantly reduced. Tamoxifen, at a daily dose of 20 mg, was administered over 2-4 months to 16 patients with gynaecomastia. Of twelve patients with painful gynaecomastia ten became painfree. Gynaecomastia regressed partially or completely in 14 patients, in only 2 was it unchanged. There was no recurrence of gynaecomastia after discontinuing tamoxifen. Side-effects did not occur. It is concluded that tamoxifen is a promising alternative to the surgical treatment of gynaecomastia.